2022年 · 第102卷第26期

Since the beginning of this century, antibody-mediated rejection (AMR) has received increasing attention in the field of renal transplantation^［1］。 More and more evidence shows that AMR is the biggest obstacle affecting the long-term survival of kidney transplantation, and about 60% of kidney transplantation failure is related to it^［2］； Moreover, the pathological mechanisms and clinical manifestations of AMR are more complex than those of cell-mediated rejection (TCMR), and the diagnosis and treatment are more difficult. Therefore, the Transplantation Technology Branch of China Medical Biotechnology Association and Shanghai Kidney Transplantation Quality Control Center organized experts to write three consensus articles^{［3, 4, 5］}The renal transplantation AMR was comprehensively and detailed. This article briefly summarizes the key clinical problems and their internal relationships.

Cervical cancer is one of the common cancers in women, and the incidence of cervical cancer ranks first among female reproductive tract cancers in China^［1］。 In developed countries, due to the popularization of cervical cancer screening and the use of human papillomavirus (HPV) vaccine, the incidence of cervical cancer has decreased significantly in recent decades, among which the decline is dominated by cervical squamous cell carcinoma, while the decline in the incidence of cervical adenocarcinoma (EAC) is relatively insignificant^［2］。 Unlike squamous cell carcinoma, the position of EAC is relatively high, and cervical exfoliative cytology is usually difficult to detect. Moreover, some EAC are not related to high-risk HPV infection, which brings great challenges to the prevention and treatment of EAC^［3］。 In recent ten years, the clinical pathology classification of EAC has been greatly changed and new understanding, which has influenced the diagnosis and treatment of EAC. This article reviews this.

Cervical cancer is the fourth most common cancer among women worldwide and the leading cause of cancer death among women in developing countries. In 2020, there were approximately 604,000 new cases of cervical cancer worldwide and approximately 341,000 deaths. With the widespread application of cervical cancer screening and the increase of human papillomavirus (HPV) infection, the occurrence of cervical cancer shows an obvious young trend.<Cervical cancer patients aged 35 accounted for about 15% to 20% of cervical cancer patients in the same period.

non-small cell lung cancer (NSCLC) accounts for more than 80% of lung cancer. There are more treatments for advanced NSCLC than for small cell lung cancer (SCLC). In addition to traditional radiotherapy and chemotherapy, individualized treatments such as molecular targeted therapy, immunotherapy, and anti-angiogenic drug therapy can be selected according to histopathology and biomarkers.